Insilico Medicine Cayman Topco and CMS launch multi-million HKD drug development partnership
I'm PortAI, I can summarize articles.
Insilico Medicine Cayman Topco has formed a strategic partnership with China Medical System Holdings Limited (CMS) to develop innovative drugs, focusing on AI-driven drug discovery for central nervous system and autoimmune diseases. The collaboration is valued at several tens of millions of Hong Kong dollars, with funding support for each R&D program. Insilico will utilize its AI platform, while CMS will provide its R&D expertise.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments